Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2001

View Archived Issues

Highlights from NeuroSearch 2000 Annual Report

NO-related cardioprotective effects of NCX-4016 confirmed in rats

Atrasentan delays disease progression in HRPCa

Agreement signed for U.S. promotion of AndroGel

AUA news: AII antagonist, ACE inhibitor protect against postischemic acute renal failure

Zelmac regulatory application voluntarily withdrawn in E.U.

STI-571 + paclitaxel as promising therapeutic strategy for prostate cancer with bone metastasis

Aventis receives approvable letter from FDA for first-in-class antibiotic

Enzyme mimetic advances to clinical trials following FDA IND approval

Thiazolidinediones potentially useful in renal cell carcinoma therapy, according to AUA presentation

Palatin's PT-141 ED treatment well tolerated in phase I trial

European authorities grant orphan drug designation for pemtumomab

FR-901228 enhances suicide cancer gene therapy by increasing transgene expression

Topical immune response modifier provides high response rate in phase II trial in sBCC

Tularik forms new company to focus on antibacterial and antifungal drugs

Oral suspension of Trileptal for epilepsy approved by FDA

Ad-RB94 gene therapy shows potential in pancreatic and squamous cell H&N cancer

Herceptin reaches market in Japan

LMW dendritic polymers and their uses reported in recent patent

Fab I inhibitors useful as antibacterial and antifungal agents

PPAR agonists from Kyorin claimed for use in metabolic diseases

BMS studies new Na+/H+ exchange inhibitors with antianginal, cardioprotective properties

Somatostatin receptor modulators in development at Takeda

Patent covers Ferring's new vasopressin V2 receptor agonists and uses

nAChR ligands particularly useful for the Rx of cognition disorders

Prous Science inaugurates Advanced Internet TTMed Channel in Anaheim

Company Profile: YM BioSciences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...